This article is more than 5 years old. Information may no longer be current.
Cellular bone allograft likely safe, effective in achieving high fusion rates
Click Here to Manage Email Alerts
Use of cellular bone allograft achieved safe and high rates of fusion among patients who underwent foot or ankle arthrodesis compared with autograft, according to recently published study results.
Researchers performed imaging among patients undergoing foot or ankle arthrodesis with cellular bone allograft (Trinity Evolution, Orthofix Inc.) at 6 weeks, 3 months, 6 months and 12 months. Patient pain, function and quality of life status were recorded for 92 patients at 6 months with 153 total arthrodesis and for 76 patients at 12 months with 129 total arthrodesis.
According to the study, the per patient fusion rates were 66.7% at 3 months, 68.5% at 6 months and 71.1% at 12 months and per joint fusion rates of 79.7% at 3 months, 81.1% at 6 months and 86.8% at 12 months.
As indicated by the American Orthopaedic Foot and Ankle Society Hindfoot scores, the postoperative function level significantly improved from baseline at each time point, according to study results. Researchers also noted significant improvements in postoperative pain levels at every time point, as well as in physical composite SF-36 scores, with improvements observed at 6 and 12 months compared with preoperative scores. Patients with diabetes or obesity had fusion rates comparable to normal patients, according to study results, and fusion correlated with improvements in function and quality of life outcomes at 6 months and 12 months.
“This study observed fusion rates using Trinity Evolution that were higher than or comparable to fusion rates in other published studies of autologous corticocancellous bone graft, a traditional gold standard used in foot and ankle procedures.” James A. Nunley, MD, stated in a press release. – by Casey Tingle
Disclosure: Jones and Nunley received grants from Orthofix Inc., who funded the study. Please see the full study for a list of the other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts